Clinuvel Pharmaceuticals Expects US Shutdown to Impact ADR Program Upgrade Deadlines

MT Newswires Live
2025/11/03

Clinuvel Pharmaceuticals (ASX:CUV) said it expects the ongoing US Federal Government shutdown to impact the deadline for the upgrade of its American Depositary Receipt Level program from level one to level two, according to a Monday filing with the Australian bourse.

The US administration expects a longer turnaround time for the review and approval of the registration statements filed with the US Securities and Exchange Commission, the filing said.

The review and approval are expected to be completed only after the shutdown is resolved, the filing added.

Shares of the company fell nearly 1% in recent Monday trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10